PainReform Ltd. (NASDAQ:PRFX) Short Interest Update

PainReform Ltd. (NASDAQ:PRFX) was the recipient of a significant decrease in short interest in February. As of February 27th, there was short interest totaling 78,499 shares, a decrease of 64.6% from the February 12th total of 221,954 shares. Approximately 29.7% of the company’s stock are sold short. Based on an average daily volume of 66,985 shares, the short-interest ratio is currently 1.2 days. Based on an average daily volume of 66,985 shares, the short-interest ratio is currently 1.2 days. Approximately 29.7% of the company’s stock are sold short.

PainReform Stock Performance

PRFX opened at $2.67 on Wednesday. The firm has a market cap of $1.07 million, a P/E ratio of 0.00 and a beta of 0.55. The business has a 50 day moving average price of $3.49 and a 200 day moving average price of $5.04. PainReform has a twelve month low of $2.50 and a twelve month high of $17.95.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of PainReform in a report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.